Infliximab in Behcet Uveitis

Not Applicable

Completed

• Conditions: Behcet uveitis; Anti tumor necrosis factor; Behcet' s disease; Infliximab; Noninfectious uveitis

• Registration Number: TCTR20200806007
• Lead Sponsor: one

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Completion: 2018-10-01
• Study Start: 2020-08-06
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

Patients that were diagnosed with Behcet's disease on the basis of the criteria proposed by the International Study Group for Behcet's disease and had related uveitis were included to the study group.
Cases that were switched from conventional IMT to IFX therapy and had a minimum of 18 months of follow-up under IFX treatment were included to the study group

Exclusion Criteria

Cases attending irregular follow-ups and those with other retinal diseases were excluded from the study. Patients with a history of tuberculosis, active HBV-HCV-HIV and fungal infections were not included to the study. Patients with malignancy, liver, renal, cardiac or pulmonary insufficiency and diagnosis or suspicion of multiple sclerosis were excluded from the study.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Control of ocular inflammation 1-3-6-12 and 24th months of the IFX treatment Standardization of Uveitis Nomenclature (SUN) Classification Scale

Secondary Outcome Measures

Name	Time	Method
Extraocular manifestations of Behcet's disease At the 6 th month of treatment initiation Patient reported outcome using a questionnaire interview